Kura Oncology Inc reports results for the quarter ended in March - Earnings Summary

Kura Oncology

03/05/2024 24:03

* Kura Oncology Inc  KURA.OQ  reported a quarterly adjusted
loss
of 59 cents​​ per share for the quarter ended in March, lower
than the same quarter last year, when the company reported EPS
of -50 cents.  The mean expectation of twelve analysts for the
quarter was for a loss of 55 cents per share. Wall Street
expected results to range from -68 cents to -44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kura Oncology Inc's reported EPS for the quarter was a
loss
of 59 cents​.
    * The company reported a quarterly loss of $49.53 million.
    * Kura Oncology Inc shares had fallen by 4.9% this
quarter and
gained 41.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Kura Oncology Inc
is $32.00 
This summary was machine generated from LSEG data May 2 at 11:03
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.55          -0.59          Missed
 Dec. 31 2023      -0.55          -0.55          Met
 Sep. 30 2023      -0.55          -0.50          Beat
 Jun. 30 2023      -0.55          -0.53          Beat